Industry News
Pharmaceutical Industry News
In this week’s Asia news recap,…
In this week's Asia news recap, AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space, while Illumina's CEO detailed the company's efforts to work with authorities in China. In addition, Astellas CEO
Becton, Dickinson and Company will…
Becton, Dickinson and Company will shell out $110 million to expand prefillable syringe production at its Columbus, Nebraska, manufacturing plant. The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about
Just a month after Johnson &…
Just a month after Johnson & Johnson reported a successful study pairing its blood cancer treatments Tecvayli and Darzalex, the company has revealed another trial win. This time, Tecvayli excelled as a solo agent, reducing
Hologic has drafted professional…
Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the guard at the center of a drive to frame testing as the “Ultimate Defense.”
With Xtandi set to lose U.S….
With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s dealmaking strategy ahead of the loss. Despite continuing to hunt for external innovation, helmsman Naoki Okamura
Even in the era of the FDA’s…
Even in the era of the FDA's Commissioner's National Priority Voucher program, Jazz Pharmaceuticals is showing that traditional priority review vouchers can catch a pretty penny.
To promote its newly launched…
To promote its newly launched nonhormonal menopause drug, Bayer is linking Lynkuet with a familiar face.
As part of its mission to make a…
As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded partnership for its Vizz prescription eye drops.
Amneal Pharmaceuticals and VantAI…
Amneal Pharmaceuticals and VantAI have joined the ranks of companies to decide that a new year demands a new look, each unveiling fresh branding aligned with their respective plans for 2026.
Much is riding on Travere…
Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis (FSGS). The indication represents a $2 billion peak sales opportunity in the U.S. alone, according to Leerink
The past year was one of…
The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out for 2026, new CEO Maziar Mike Doustdar appears confident in his commercial
While the $80 billion revenue…
While the $80 billion revenue target AstraZeneca set for 2030 is already "very much within reach," Chief Financial Officer Aradhana Sarin said the company would grow even more confident if it can repeat the phase
Ionis Pharmaceuticals’ launch of…
Ionis Pharmaceuticals’ launch of Tryngolza (olezarsen) is off to a flying start as a treatment for familial chylomicronemia syndrome. With the California drugmaker preparing to roll Tryngolza out in a new indication, it has significantly
Less than four months after…
Less than four months after rejecting Sentynl Therapeutics and Cyprium Therapeutics’ treatment for Menkes disease, the FDA has given the partners a thumbs-up, blessing Zycubo as the first approved therapy in the U.S. for the
AbbVie has announced a deal with…
AbbVie has announced a deal with the White House to lower the prices of certain medicines on Medicaid. At the same time, the Chicago-based company pledged $100 billion in U.S. R&D and capital investments, including
Leo Pharma CEO Christophe Bourdon…
Leo Pharma CEO Christophe Bourdon is eager to make additional strides on the new era of growth he’s fostered since taking over in 2022, he said in an interview on the sidelines of the J.P.
David Mitchell, Who Led Fight on Drug Prices, Dies at 75
After receiving a diagnosis of terminal cancer, he used his experience in public relations to draw attention to the skyrocketing cost of medication.
F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds
A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.
SAN FRANCISCO—Bristol Myers…
SAN FRANCISCO—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the company’s capital
In a preliminary report of its…
In a preliminary report of its 2025 results, Apellis said that sales of its geographic atrophy (GA) drug Syfovre came in at $587 million for the year, a 4% decline from its 2024 figure of